Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-Label Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral Ibrexafungerp (SCY-078) as an Emergency Use Treatment for Patients With Candidiasis, Including Candidemia, Caused by Candida Auris

Trial Profile

Open-Label Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral Ibrexafungerp (SCY-078) as an Emergency Use Treatment for Patients With Candidiasis, Including Candidemia, Caused by Candida Auris

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 21 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibrexafungerp (Primary)
  • Indications Candidaemia; Invasive candidiasis
  • Focus Registrational; Therapeutic Use
  • Acronyms CARES
  • Sponsors SCYNEXIS
  • Most Recent Events

    • 14 Aug 2023 According to a SCYNEXIS media release, interim data from this trial presented at the 33rd Annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2023
    • 25 Jun 2023 Status changed from active, no longer recruiting to completed.
    • 12 May 2023 According to Scynexis media release, company has announced the closing of its previously announced exclusive license agreement with GSK plc. Under the license agreement, SCYNEXIS will continue executing the Phase 3 program for invasive candidiasis (IC).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top